Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.018641% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.003582% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.65 |
| Open | 3.62 |
| 1-Year Change | 6.78% |
| Day's Range | 3.62 - 3.74 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 3.63 | 0.05 | 1.40% | 3.58 | 3.77 | 3.58 |
| Feb 20, 2025 | 3.65 | 0.06 | 1.67% | 3.59 | 3.72 | 3.57 |
| Feb 19, 2025 | 3.66 | -0.08 | -2.14% | 3.74 | 3.75 | 3.65 |
| Feb 18, 2025 | 3.76 | 0.08 | 2.17% | 3.68 | 3.80 | 3.68 |
| Feb 17, 2025 | 3.74 | -0.07 | -1.84% | 3.81 | 3.92 | 3.69 |
| Feb 14, 2025 | 3.86 | 0.04 | 1.05% | 3.82 | 3.91 | 3.78 |
| Feb 13, 2025 | 3.82 | -0.01 | -0.26% | 3.83 | 3.92 | 3.73 |
| Feb 12, 2025 | 3.84 | 0.18 | 4.92% | 3.66 | 3.93 | 3.64 |
| Feb 11, 2025 | 3.74 | 0.05 | 1.36% | 3.69 | 3.79 | 3.69 |
| Feb 10, 2025 | 3.69 | -0.07 | -1.86% | 3.76 | 3.81 | 3.69 |
| Feb 7, 2025 | 3.65 | -0.07 | -1.88% | 3.72 | 3.79 | 3.65 |
| Feb 6, 2025 | 3.80 | 0.07 | 1.88% | 3.73 | 3.85 | 3.73 |
| Feb 5, 2025 | 3.64 | 0.06 | 1.68% | 3.58 | 3.76 | 3.52 |
| Feb 4, 2025 | 3.58 | 0.05 | 1.42% | 3.53 | 3.65 | 3.51 |
| Feb 3, 2025 | 3.51 | 0.12 | 3.54% | 3.39 | 3.60 | 3.36 |
| Jan 31, 2025 | 3.55 | 0.01 | 0.28% | 3.54 | 3.71 | 3.49 |
| Jan 30, 2025 | 3.66 | 0.12 | 3.39% | 3.54 | 3.85 | 3.45 |
| Jan 29, 2025 | 3.51 | 0.12 | 3.54% | 3.39 | 3.65 | 3.39 |
| Jan 28, 2025 | 3.46 | 0.08 | 2.37% | 3.38 | 3.48 | 3.35 |
| Jan 27, 2025 | 3.39 | 0.04 | 1.19% | 3.35 | 3.43 | 3.32 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
| Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com